In vitro antifungal susceptibility profile of Iranian Fusarium isolates: Emphasising on the potent inhibitory effect of efinaconazole compared to other drugs

Fusarium species are opportunistic human pathogens that remarkably cause fungal infections ranging from superficial to fatal invasive disseminated infections. Fusarium species are notoriously resistant to the majority of antifungal agents.

[1]  Kuo-Hsuan Hung,et al.  Fusarium Keratitis in Taiwan: Molecular Identification, Antifungal Susceptibilities, and Clinical Features , 2022, Journal of fungi.

[2]  H. Badali,et al.  Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole , 2022, Mycoses.

[3]  R. Funk,et al.  Blowin’ in the Wind: Wind Dispersal Ability of Phytopathogenic Fusarium in a Wind Tunnel Experiment , 2021, Atmosphere.

[4]  M. Mwanza,et al.  Fusarium Mycotoxins, Their Metabolites (Free, Emerging, and Masked), Food Safety Concerns, and Health Impacts , 2021, International Journal of Environmental Research and Public Health.

[5]  E. Anaissie,et al.  Invasive Fusariosis in Patients with Hematologic Diseases , 2021, Journal of fungi.

[6]  Ruoyu Li,et al.  Molecular and MALDI‐ToF MS differentiation and antifungal susceptibility of prevalent clinical Fusarium species in China , 2021, Mycoses.

[7]  E. Berkow,et al.  In Vitro Activity of Novel Antifungal Olorofim against Filamentous Fungi and Comparison to Eight Other Antifungal Agents , 2021, Journal of fungi.

[8]  S. Ansari,et al.  In Vitro Antifungal Activity of Luliconazole, Efinaconazole, and Nine Comparators Against Aspergillus and Candida Strains Isolated from Otomycosis , 2021, Jundishapur Journal of Microbiology.

[9]  H. Badali,et al.  In vitro activity of olorofim against clinical isolates of the Fusarium oxysporum and Fusarium solani species complexes , 2021, Mycoses.

[10]  A. Al‐Hatmi,et al.  Fusariosis: an update on therapeutic options for management , 2021 .

[11]  J. Y. Kim,et al.  Clinical Features and Outcomes of Invasive Fusariosis: A Case Series in a Single Center with Literature Review , 2021, Infection & chemotherapy.

[12]  H. Hof.  The Medical Relevance of Fusarium spp. , 2020, Journal of fungi.

[13]  M. Machouart,et al.  Fusarium infections: Epidemiological aspects over 10 years in a university hospital in France. , 2020, Journal of infection and public health.

[14]  S. Dolatabadi,et al.  Phylogenetic Analysis of Clinically Relevant Fusarium Species in Iran , 2020, Mycopathologia.

[15]  A. Fuentefria,et al.  Human fusariosis: An emerging infection that is difficult to treat , 2020, Revista da Sociedade Brasileira de Medicina Tropical.

[16]  S. Rampersad.  Pathogenomics and Management of Fusarium Diseases in Plants , 2020, Pathogens.

[17]  M. Gharaghani,et al.  Luliconazole, a highly effective imidazole, against Fusarium species complexes , 2020, Medical Microbiology and Immunology.

[18]  H. Badali,et al.  Antifungal Activity of a Novel Triazole, Efinaconazole and Nine Comparators against 354 Molecularly Identified Aspergillus Isolates , 2020, Mycopathologia.

[19]  E. Toropova,et al.  Fungi ecological niches of the genus Fusarium Link. , 2020, BIO Web of Conferences.

[20]  N. Singla,et al.  Molecular identification of Fusarium species complex isolated from clinical samples and its antifungal susceptibility patterns , 2019, Current medical mycology.

[21]  A. Olaniran,et al.  Occurrence, toxicity, production and detection of Fusarium mycotoxin: a review , 2019, Food Production, Processing and Nutrition.

[22]  C. Hennequin,et al.  In Vitro Susceptibility of Fusarium to Isavuconazole , 2019, Antimicrobial Agents and Chemotherapy.

[23]  J. Meis,et al.  Multiresistant Fusarium Pathogens on Plants and Humans: Solutions in (from) the Antifungal Pipeline? , 2019, Infection and drug resistance.

[24]  M. Burton,et al.  In Vitro Activity of Chlorhexidine Compared with Seven Antifungal Agents against 98 Fusarium Isolates Recovered from Fungal Keratitis Patients , 2019, Antimicrobial Agents and Chemotherapy.

[25]  J. Meis,et al.  Molecular Characterization and Antifungal Susceptibility of Clinical Fusarium Species From Brazil , 2019, Front. Microbiol..

[26]  H. Yamaguchi,et al.  Efficacy of Luliconazole Against Broad-Range Filamentous Fungi Including Fusarium solani Species Complex Causing Fungal Keratitis , 2018, Cornea.

[27]  A. Porro,et al.  Disseminated fusariosis with cutaneous involvement in hematologic malignancies: report of six cases with high mortality rate* , 2018, Anais brasileiros de dermatologia.

[28]  A. Fuentefria,et al.  In vitro susceptibility and multilocus sequence typing of Fusarium isolates causing keratitis. , 2018, Journal de mycologie medicale.

[29]  H. Badali,et al.  Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species , 2018, Antimicrobial Agents and Chemotherapy.

[30]  H. Badali,et al.  In Vitro Antifungal Activity of Novel Triazole Efinaconazole and Five Comparators against Dermatophyte Isolates , 2018, Antimicrobial Agents and Chemotherapy.

[31]  Savitri Sharma,et al.  Phylogenetic Diversity and In Vitro Susceptibility Profiles of Human Pathogenic Members of the Fusarium fujikuroi Species Complex Isolated from South India , 2018, Mycopathologia.

[32]  S. Ranque,et al.  Current antifungal treatment of fusariosis. , 2017, International journal of antimicrobial agents.

[33]  Adelaida Gaviria-Rivera,et al.  In vitro antifungal susceptibility of clinical isolates of Fusarium from Colombia. , 2017, Revista de salud publica.

[34]  H. Badali,et al.  In Vitro Activities of Luliconazole, Lanoconazole, and Efinaconazole Compared with Those of Five Antifungal Drugs against Melanized Fungi and Relatives , 2017, Antimicrobial Agents and Chemotherapy.

[35]  A. Fuentefria,et al.  Genetic diversity and antifungal susceptibility of Fusarium isolates in onychomycosis , 2017, Mycoses.

[36]  Savitri Sharma,et al.  An Assessment of In Vitro Antifungal Activities of Efinaconazole and Itraconazole against Common Non-Dermatophyte Fungi Causing Onychomycosis , 2017, Journal of fungi.

[37]  J. Meis,et al.  Antifungal Susceptibility Testing of Fusarium: A Practical Approach , 2017, Journal of fungi.

[38]  M. Cuenca‐Estrella,et al.  Changes in the epidemiological landscape of invasive mould infections and disease , 2017, The Journal of antimicrobial chemotherapy.

[39]  H. Badali,et al.  Potent Activities of Novel Imidazoles Lanoconazole and Luliconazole against a Collection of Azole-Resistant and -Susceptible Aspergillus fumigatus Strains , 2016, Antimicrobial Agents and Chemotherapy.

[40]  J. Alffenaar,et al.  Therapeutic Drug Monitoring of Posaconazole: an Update , 2016, Current Fungal Infection Reports.

[41]  S. Seyedmousavi,et al.  Genotyping and In Vitro Antifungal Susceptibility Testing of Fusarium Isolates from Onychomycosis in India , 2016, Mycopathologia.

[42]  J. Meis,et al.  Fusarium: Molecular Diversity and Intrinsic Drug Resistance , 2016, PLoS pathogens.

[43]  J. Meis,et al.  Antifungal Susceptibility and Phylogeny of Opportunistic Members of the Genus Fusarium Causing Human Keratomycosis in South India. , 2016, Medical mycology.

[44]  J. Meis,et al.  Global molecular epidemiology and genetic diversity of Fusarium, a significant emerging group of human opportunists from 1958 to 2015 , 2016, Emerging microbes & infections.

[45]  A. A. Hatmi.  Phylogeny, diagnostics and antifungal susceptibility of clinically relevant Fusarium species , 2016 .

[46]  J. Meis,et al.  Keratitis by Fusarium temperatum, a novel opportunist , 2014, BMC Infectious Diseases.

[47]  Sohita Dhillon,et al.  Efinaconazole: First Global Approval , 2013, Drugs.

[48]  A. Fothergill,et al.  Comparison of In Vitro Antifungal Activities of Efinaconazole and Currently Available Antifungal Agents against a Variety of Pathogenic Fungi Associated with Onychomycosis , 2013, Antimicrobial Agents and Chemotherapy.

[49]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of filamentous fungi : Approved standard , 2008 .

[50]  H. Yamaguchi,et al.  In vitro activity of novel imidazole antifungal agent NND-502 against Malassezia species. , 2003, International journal of antimicrobial agents.

[51]  R. Ploetz,et al.  Multiple evolutionary origins of the fungus causing Panama disease of banana: concordant evidence from nuclear and mitochondrial gene genealogies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.